test directorySearch Results
Click here to search again.
Test Name:
Valproic Acid, Total
- SBMF No:
31032 - Performance Lab Name:
Automated Lab - Test Mnemonic:
VALPR - ABN:
Not required - CPT Code:
80164 - LOINC Code:
4086-5 - Also Known As:
Depakene®
Depakote® - Spec Type:
Serum - Spec Container:
Red top (serum) tube - Alt Spec Type:
Plasma - Alt Spec Container:
Green top (lithium or sodium heparin) tube - Pref Vol:
0.5 mL - Min Vol:
0.2 mL - Fasting:
No - Spec Collect:
Do not use gel-barrier tubes for specimen collection
Routine venipuncture - Spec Process:
Promptly centrifuge 15 minutes
Immediately transfer plasma to separate plastic tube - Spec Store Transport:
Refrigerated - Spec Stability:
1 week refrigerated (2-8°C)
1 month frozen (-20°C) – Do not use frost-free units that undergo repeated freeze/thaw cycles - Spec Remarks:
Some therapeutic drug concentrations are reduced when the sample is stored in a separator tube for a prolonged period of time (greater than 2 hours) - Methodology:
Enzyme Immunoassay (EIA) - Use:
Used in the diagnosis and treatment of valproic acid overdose and in monitoring levels of valproic acid to ensure appropriate therapy - Clinical Significance:
Valproic acid (VPA; 2-propylpentanoic acid; Depakene ®) is a relatively new anticonvulsant medication which is used chiefly for the treatment of primary and secondary generalized seizures, but is also effective against absence seizures. It is particularly effective in myoclonus, and is the drug of choice in photosensitive epilepsy. Although VPA is used in conjunction with other anti-epileptic medications, more recent studies have shown benefits of converting treatment to monotherapy with VPA. Also, a growing body of evidence suggests that VPA is useful in treatment of affective disorders; in particular, lithium-insensitive bipolar disorders.At therapeutic concentrations, over 90% of VPA in the circulation is bound to plasma proteins, primarily albumin. Binding is saturable, and at high VPA concentrations, the free fraction increases. Other compounds can compete for VPA binding to albumin; these include salicylic acid and free fatty acids. The concentration of VPA in cerebrospinal fluid is correlated to both the total and unbound concentrations of the drug in plasma.VPA is converted to a complex mixture of metabolites via b- and w-oxidation and conjugation. Some metabolites show significant anti-convulsant activity, while others may be responsible for some of the drug’s toxic side effects.VPA has the fewest adverse effects of all the widely-used anti-epileptic agents. The most common side effects are gastrointestinal disturbances such as nausea and vomiting. Some incidences of tremor, coma or stupor have been noted; these often occur in conjunction with co-administration of other anti-epileptic drugs. Rare occurrences of hepatic failure, Reye-like syndrome, pancreatitis or thrombocytopenia are thought to be individualized reactions unrelated to drug levels.Pharmacokinetics of VPA are highly variable, depending on the form of the drug and route of administration, as well as individual variations in volume of distribution, metabolism and clearance. Moreover, co-administration of other anti-epileptic drugs can significantly affect VPA metabolism. Therefore, monitoring VPA concentrations during therapy is essential in order to provide the physician with an indicator for adjusting dosage. - Reference Range:
50.0-100.0 µg/mL - Critical High Value:
175.1 µg/mL - Day Run:
Sun-Sat (daily) - Time Run:
As received - Time Reported:
4 hours - Test Type:
TOX-TDM
